TICKERNERD
Menu
LENZLENZHealthcare · Biotechnology

LENZ Stock Forecast: LENZ Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$3.53

The 7 Wall Street analysts covering LENZ Therapeutics, Inc. hold a median 12-month price target of $10 — +183.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$110.9M
Ticker Nerd rank
25 / 100
Median analyst target
$10
Analysts covering
7
Revenue$5.5M+9.7% y/y
Operating income−$34.2M
Net income−$31.9M
Free cash flow−$38.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

LENZ stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores LENZ Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
25 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
74
Revisions
68
Quality
48
Accruals
47
Volatility
42
Issuance
39
Growth
24
Value
8
Momentum
1

Size (74): Smaller than most of the companies we track.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LENZ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LENZ, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says7 analysts
5 Buy2 Hold0 Sell
Low $7Median $10High $60

The green dot is the last close — the median target sits +183.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Aug 2026Piper SandlerMaintainsNeutral$12 → $7.00
7 July 2026HC Wainwright & Co.ReiteratesBuy$38
7 July 2026HC Wainwright & Co.ReiteratesBuy—
13 May 2026CitigroupMaintainsBuy—
12 May 2026HC Wainwright & Co.MaintainsBuy—
12 May 2026Piper SandlerDowngradeNeutral—
21 Apr 2026HC Wainwright & Co.MaintainsBuy—
26 Mar 2026CitigroupMaintainsBuy—
25 Mar 2026B of A SecuritiesMaintainsBuy—
20 Oct 2025Raymond JamesReiteratesOutperform—
10 Oct 2025Piper SandlerMaintainsOverweight—
1 Aug 2025CitigroupMaintainsBuy—
1 Aug 2025HC Wainwright & Co.MaintainsBuy—
31 July 2025CitigroupMaintainsBuy—
31 July 2025Raymond JamesMaintainsOutperform—
28 July 2025HC Wainwright & Co.MaintainsBuy—
8 May 2025HC Wainwright & Co.ReiteratesBuy—
16 Apr 2025HC Wainwright & Co.ReiteratesBuy—
14 Apr 2025Piper SandlerMaintainsOverweight—
20 Mar 2025CitigroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LENZ appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LENZ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
2
Fundamentals

LENZ Therapeutics, Inc. (LENZ) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
48.0×

Cheaper than 15% of US stocks

Price / sales
5.2×

Cheaper than 24% of US stocks

Price / book
0.5×

Cheaper than 84% of US stocks

EV / EBITDA
0.8×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
9.7%

Higher than 51% of US stocks

Earnings growth (YoY)
9.7%

Higher than 48% of US stocks

Gross margin
94.9%

Higher than 98% of US stocks

Operating margin
−622.9%

Higher than 7% of US stocks

Net margin
97.8%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−59.2%

Higher than 19% of US stocks

Return on assets
−37.4%

Higher than 11% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

LENZ Therapeutics, Inc. (LENZ) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • LENZ Therapeutics, Inc. has a market value of $110.9M and an enterprise value of −$108.5M.

  • Revenue in the twelve months to 30 June 2026: $21.5M. The latest quarter grew 9.7% year on year.

  • Net income over the same four quarters: −$126.0M, a −586.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−4.09.

  • Free cash flow in the twelve months to 30 June 2026: −$114.4M.

  • Shares outstanding: 31.4M.

  • Trailing P/E: 48.0×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • LENZ Therapeutics, Inc. employs 152 people — $141K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

LENZ vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LENZLENZ Therapeutics, Inc.$110.9M
25
VANIVivani Medical, Inc.$111.0M
47
GNLXGenelux Corp.$111.8M
19
UNCYUnicycive Therapeutics, Inc.$108.7M
43
PMVPPMV Pharmaceuticals, Inc.$112.5M
79
INOInovio Pharmaceuticals, Inc.$112.6M
43
RANIRani Therapeutics Holdings, Inc.$108.0M
68

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own LENZ Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LENZ news & analysis

These beaten-down stocks could bounce back in January, if history is any guide

Market Watch · 21 Sept 2026neutral

Market Watch reports that tax-loss selling is expected to artificially depress 20 beaten-down stocks in the fourth quarter, and based on historical patterns these stocks could bounce back in January. The article does not specifically name LENZ Therapeutics among those 20 stocks.

Why it matters — A LENZ watcher would care because if the company is among the stocks affected by year-end tax-loss selling, it could see a seasonal rebound in the new year without any change in fundamentals.

LENZ Therapeutics: Still Speculative But Priced For Disasters

Seeking Alpha · 4 Sept 2026neutral

LENZ Therapeutics received a 'Strong Buy' rating with a fair value estimate of $21.3, implying roughly 266% upside, with peak US Vizz sales modeled at $375M. However, the stock remains speculative due to single-product risk, high SG&A costs, its uninsured status, and rising competition, so the analysis keeps position sizing limited.

Why it matters — LENZ watchers would care because the analysis highlights both a large expected upside for Vizz and the key risks—single-product dependence, high expenses, lack of insurance coverage, and competition—that continue to make the stock speculative.

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

Seeking Alpha published the transcript of LENZ Therapeutics, Inc.'s Q2 2026 earnings call. The transcript covers management's discussion of the company's second-quarter performance and outlook.

Why it matters — LENZ watchers would use the earnings call transcript to hear management's own commentary on quarterly results and guidance directly from the company.

LENZ Therapeutics Q2 Earnings Call Highlights

MarketBeat · 11 Aug 2026positive

LENZ Therapeutics reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and increased prescription activity following the July rollout of national TV advertising and a telehealth access option.

Why it matters — The update offers LENZ watchers a closer look at early commercial traction for its product VIZZ, including revenue figures and prescription trends.

FAQ

Frequently asked questions about LENZ stock

What is the LENZ stock price forecast for 2026-2027?

The 7 Wall Street analysts covering LENZ Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $7 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LENZ stock a buy right now?

Of the 7 analysts covering LENZ Therapeutics, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LENZ Therapeutics, Inc. 25 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LENZ?

As at 8 Oct 2026, LENZ Therapeutics, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (74 of 100).

Will LENZ stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +183.3% from the last close, and Ticker Nerd's factor model ranks LENZ Therapeutics, Inc. 25 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LENZ stock forecast for 2030?

No analyst covering LENZ Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LENZ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $60 over the next 12 months.

What does LENZ Therapeutics, Inc. do?

LENZ Therapeutics, Inc. is a pharmaceutical and biotechnology company focused on commercializing ophthalmic treatments that improve vision.

What is the latest news on LENZ?

The most recent item we track (Market Watch, 21 Sept 2026): "These beaten-down stocks could bounce back in January, if history is any guide". Market Watch reports that tax-loss selling is expected to artificially depress 20 beaten-down stocks in the fourth quarter, and based on historical patterns these stocks could bounce back in January. The article does not specifically name LENZ Therapeutics among those 20 stocks.

Company

About LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. is a pharmaceutical and biotechnology company focused on commercializing ophthalmic treatments that improve vision. Its primary product is VIZZ, an aceclidine-based eye drop approved for the treatment of presbyopia, the age-related loss of near vision. The company develops eye-care therapies designed for convenient daily use, with an emphasis on preservative-free, single-use formulations that support patient adherence and ease of administration. LENZ Therapeutics serves the prescription eye-care market and concentrates on addressing a common vision condition affecting adults worldwide. Headquartered in Solana Beach, California, the company plays a specialized role in the broader ophthalmology and biopharmaceutical sectors by bringing non-surgical treatment options to market for presbyopia management.

CEO Mr. Evert B. Schimmelpennink · 152 employees · United States · https://www.lenz-tx.com